FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997663316> ?p ?o ?g. }

• W2997663316 endingPage "101920" @default.
• W2997663316 startingPage "101920" @default.
• W2997663316 abstract "Tocilizumab (TCZ), a humanized monoclonal antibody against the interleukin-6 receptor, is approved for treatment of rheumatoid arthritis and several other immune-mediated disorders. Off-label use of the intravenous formulation of tocilizumab for Neuromyelitis Optica Spectrum Disorder (NMOSD) decreased relapse rates in two small case series. However, treatment protocol that requires frequent intravenous infusions may adversely affect adherence to therapy, especially in the more disabled patients, thereby reducing effectiveness. A subcutaneous formulation of tocilizumab was shown to be noninferior to the IV formulation for approved rheumatologic diseases. The effectiveness of subcutaneous TCZ for NMOSD is unknown.We retrospectively reviewed clinical, radiological and serological data on all NMOSD patients who received subcutaneous TCZ in two tertiary referral centers between 2014-2019.Twelve NMOSD patients who received at least 6 months of subcutaneous TCZ were identified. Eleven were female; mean age was 46.9 ± 14.5 years and mean disease duration was 6.6 ± 4.6 years. Seven patients were seropositive for AQP-4 antibodies, two - for MOG-IgG antibodies, and three were doubly seronegative. During subcutaneous TCZ treatment, eight patients (66.6%) were relapse-free, one patient (8.3%) experienced 1 relapse, two patients (16.6%) - 2 relapses, and one patient (8.3%) - 3 relapses. The median relapse rate within 1 year after starting subcutaneous TCZ - 0 (interquartile range =1.75-0) - was significantly lower than in the year prior to treatment initiation (2, interquartile range = 4.0-0.25; p = 0.04). Overall, the annual relapse rate (ARR) decreased from a median of 2 (interquartile range = 5.75-1.29) prior to subcutaneous TCZ to 0 (interquartile range= = 1.0-0) on treatment (p = 0.0015). One TCZ-treated patient died following a severe myelitis attack.Effectiveness of subcutaneous TCZ in NMOSD appears to be similar to that reported for the IV formulation and has an advantage of at-home administration. Prospective, comparative studies of subcutaneous TCZ for NMOSD are warranted." @default.
• W2997663316 created "2020-01-10" @default.
• W2997663316 creator A5026541269 @default.
• W2997663316 creator A5027362230 @default.
• W2997663316 creator A5059662648 @default.
• W2997663316 creator A5061215554 @default.
• W2997663316 creator A5068351536 @default.
• W2997663316 date "2020-04-01" @default.
• W2997663316 modified "2023-10-02" @default.
• W2997663316 title "Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders" @default.
• W2997663316 cites W1829342801 @default.
• W2997663316 cites W1991019975 @default.
• W2997663316 cites W2007147688 @default.
• W2997663316 cites W2009114633 @default.
• W2997663316 cites W2013278685 @default.
• W2997663316 cites W2038941725 @default.
• W2997663316 cites W2047163949 @default.
• W2997663316 cites W2072799381 @default.
• W2997663316 cites W2096069651 @default.
• W2997663316 cites W2100093402 @default.
• W2997663316 cites W2110217426 @default.
• W2997663316 cites W2120238028 @default.
• W2997663316 cites W2129229339 @default.
• W2997663316 cites W2135249078 @default.
• W2997663316 cites W2150598981 @default.
• W2997663316 cites W2162576364 @default.
• W2997663316 cites W2208791667 @default.
• W2997663316 cites W2248796441 @default.
• W2997663316 cites W2291779617 @default.
• W2997663316 cites W2564793794 @default.
• W2997663316 cites W2621138762 @default.
• W2997663316 cites W2737436316 @default.
• W2997663316 cites W2747647717 @default.
• W2997663316 cites W2780830744 @default.
• W2997663316 cites W2796022095 @default.
• W2997663316 cites W2901863094 @default.
• W2997663316 cites W2905076420 @default.
• W2997663316 cites W2924068561 @default.
• W2997663316 cites W2943416206 @default.
• W2997663316 cites W2972221943 @default.
• W2997663316 cites W2991438804 @default.
• W2997663316 cites W4251248715 @default.
• W2997663316 doi "https://doi.org/10.1016/j.msard.2019.101920" @default.
• W2997663316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31918241" @default.
• W2997663316 hasPublicationYear "2020" @default.
• W2997663316 type Work @default.
• W2997663316 sameAs 2997663316 @default.
• W2997663316 citedByCount "33" @default.
• W2997663316 countsByYear W29976633162020 @default.
• W2997663316 countsByYear W29976633162021 @default.
• W2997663316 countsByYear W29976633162022 @default.
• W2997663316 countsByYear W29976633162023 @default.
• W2997663316 crossrefType "journal-article" @default.
• W2997663316 hasAuthorship W2997663316A5026541269 @default.
• W2997663316 hasAuthorship W2997663316A5027362230 @default.
• W2997663316 hasAuthorship W2997663316A5059662648 @default.
• W2997663316 hasAuthorship W2997663316A5061215554 @default.
• W2997663316 hasAuthorship W2997663316A5068351536 @default.
• W2997663316 hasConcept C119060515 @default.
• W2997663316 hasConcept C126322002 @default.
• W2997663316 hasConcept C141071460 @default.
• W2997663316 hasConcept C203014093 @default.
• W2997663316 hasConcept C2777178219 @default.
• W2997663316 hasConcept C2777575956 @default.
• W2997663316 hasConcept C2780640218 @default.
• W2997663316 hasConcept C2781137167 @default.
• W2997663316 hasConcept C71924100 @default.
• W2997663316 hasConcept C90924648 @default.
• W2997663316 hasConceptScore W2997663316C119060515 @default.
• W2997663316 hasConceptScore W2997663316C126322002 @default.
• W2997663316 hasConceptScore W2997663316C141071460 @default.
• W2997663316 hasConceptScore W2997663316C203014093 @default.
• W2997663316 hasConceptScore W2997663316C2777178219 @default.
• W2997663316 hasConceptScore W2997663316C2777575956 @default.
• W2997663316 hasConceptScore W2997663316C2780640218 @default.
• W2997663316 hasConceptScore W2997663316C2781137167 @default.
• W2997663316 hasConceptScore W2997663316C71924100 @default.
• W2997663316 hasConceptScore W2997663316C90924648 @default.
• W2997663316 hasFunder F4320306161 @default.
• W2997663316 hasFunder F4320307772 @default.
• W2997663316 hasFunder F4320308604 @default.
• W2997663316 hasFunder F4320309052 @default.
• W2997663316 hasFunder F4320310242 @default.
• W2997663316 hasFunder F4320332193 @default.
• W2997663316 hasFunder F4320332200 @default.
• W2997663316 hasLocation W29976633161 @default.
• W2997663316 hasLocation W29976633162 @default.
• W2997663316 hasOpenAccess W2997663316 @default.
• W2997663316 hasPrimaryLocation W29976633161 @default.
• W2997663316 hasRelatedWork W1829342801 @default.
• W2997663316 hasRelatedWork W2047316467 @default.
• W2997663316 hasRelatedWork W2061253854 @default.
• W2997663316 hasRelatedWork W2135221496 @default.
• W2997663316 hasRelatedWork W2156283049 @default.
• W2997663316 hasRelatedWork W2970100988 @default.
• W2997663316 hasRelatedWork W2997663316 @default.
• W2997663316 hasRelatedWork W3209686377 @default.
• W2997663316 hasRelatedWork W4251265868 @default.

• next